Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Kevin J Harrington"'
Autor:
Tamara Rordorf, Makoto Tahara, Ramona F. Swaby, Denis Soulières, Joy Yang Ge, Richard Greil, Wan Zamaniah Wan Ishak, Danny Rischin, Brett G.M. Hughes, Thorsten Fuereder, Burak Gumuscu, Kevin J. Harrington, Amanda Psyrri, Neus Baste, Barbara Burtness, Prakash Neupane, Gilberto de Castro, Nuttapong Ngamphaiboon, Åse Bratland, Ricard Mesia
Publikováno v:
Cancer Research. 80:LB-258
Introduction: In the phase 3 KEYNOTE-048 trial (NCT02358031) in R/M HNSCC, first-line pembrolizumab (P) monotherapy vs EXTREME (E; chemotherapy [C] + cetuximab) improved overall survival (OS) in PD-L1 combined positive score (CPS) ≥20 and CPS ≥1
Autor:
Djuro Karanovic, Mitesh J. Borad, Diwakar Davar, Maria Schwaederle, Dmitriy Zamarin, Grace K. Dy, Danielle M. Townsley, Kevin J. Harrington, Evanthia Galanis, Beth Kelly
Publikováno v:
Cancer Research. 80:CT244-CT244
Background: Oncolytic viruses selectively infect tumors and activate antitumor immune responses via innate and adaptive pathways, which may potentiate the efficacy of immune checkpoint inhibitors. MEDI5395 is a recombinant Newcastle disease virus inc
Autor:
Robert S. Coffin, Joan N. Kyula, Howard L. Kaufman, Victoria Roulstone, Linta Juncheria, Suzanne Thomas, Kevin J. Harrington
Publikováno v:
Cancer Research. 79:1470-1470
A number of oncolytic viruses have shown single agent clinical activity and evidence of clinical synergy with immune checkpoint blockade. However, not all patients respond, and as yet most of the promising clinical data have been generated in patient
Autor:
Matthew G Krebs, Kevin J. Harrington, S.Y. Amy Cheung, Alienor Berges, Simon Smith, Alan Lau, Brunella Felicetti, Andrew J. Pierce, James W.T. Yates, Emma Dean, Simon J. Hollingsworth, Christine Stephens, Nathan Standifer
Publikováno v:
Cancer Research. 78:CT118-CT118
Introduction: AZD6738 is a potent inhibitor of the ATR protein kinase that is being tested in patients with solid malignancies. In Phase I dose escalation studies, AZD6738 was dosed as monotherapy (continuous schedule from 40 - 480 mg per day), or in
Autor:
Jonathan D. Cheng, Denis Soulières, Ramona F. Swaby, Lisa Licitra, Ainara Soria, Myung-Ju Ahn, Ezra E.W. Cohen, José Dinis, Kevin J. Harrington, Christophe Le Tourneau, Ranee Mehra, Barbara Burtness, P. Zhang, Jean-Pascal Machiels, Nicolas Mach
Publikováno v:
Cancer Research. 78:CT115-CT115
Background: It was known that survival data were outstanding on several patients (pts) when the final analysis of the multinational, open-label, phase 3 KEYNOTE-040 study (NCT02252042) of pembro vs SOC for recurrent or metastatic head and neck squamo
Autor:
Makoto Tahara, Omar Jabado, Mark Lynch, Caroline Even, A. Dimitrios Colevas, Everett E. Vokes, Cheryl Ho, Somnath Bandyopadhyay, Manish Monga, Lisa Licitra, Robert L. Ferris, Joël Guigay, George R. Blumenschein, Robert I. Haddad, Henry Kao, Kevin J. Harrington, Jérôme Fayette, Maura L. Gillison
Publikováno v:
Cancer Research. 77:CT022-CT022
Introduction: Recent studies indicated that specific intestinal microbiota may modulate efficacy of anti-PD-1 and anti-CTLA-4 immunotherapy in preclinical tumor models (Sivan et al, Science. 2015;350:1084-9; Vétizou et al, Science. 2015;350:1079-84)
Autor:
Hardev Pandha, Jonathan E. Rosenberg, Kevin J. Harrington, Alan Melcher, Rachael E. Sandborn, C Ralph, Sumati Gupta, David Ross Kaufman, Darren R. Shafren, Emmett V. Schmidt, Wallace Akerley, Mark Grose, Charles M. Rudin
Publikováno v:
Cancer Research. 77:CT115-CT115
Background: Coxsackievirus A21 (CVA21, CAVATAK) is a naturally occurring ICAM-1 targeted oncolytic immunotherapeutic virus. Pembrolizumab is a human programmed death receptor-1 (PD-1) blocking antibody that has yielded significant solid tumor respons
Autor:
Manish Monga, Everett E. Vokes, Makoto Tahara, Kevin J. Harrington, Henry Kao, Cheryl Ho, Lisa Licitra, Stefan Kasper, Francis P. Worden, Fernando Concha-Benavente, George R. Blumenschein, Joël Guigay, Danielle Greenawalt, A. Dimitrios Colevas, Nabil F. Saba, Mark Lynch, Caroline Even, Chelsea Jin, Robert I. Haddad, Robert L. Ferris, Jérôme Fayette, Maura L. Gillison
Publikováno v:
Cancer Research. 77:CT021-CT021
Introduction: In the phase 3 study CheckMate 141 (NCT02105636), patients with platinum-refractory head and neck squamous cell carcinoma treated with nivolumab (NIVO) had longer median overall survival (OS) (7.5 vs 5.1 months; P=0.01) and a higher obj
Autor:
G. Ross, Kin Woo, Aude Espinasse, Eleni Josephides, Simon Smith, Sally Ellis, Kabir Mohammed, Magnus T. Dillon, Kevin J. Harrington, Lyndall McLellan, Sola Adeleke, Lorna Grove, James Spicer, Martin Forster
Publikováno v:
Cancer Research. 77:CT084-CT084
Many cancers have high levels of replication stress and a poorly functional G1/S DNA damage checkpoint. This may render them more susceptible than normal tissues to inhibition of ATR, an apical kinase in the DNA damage response and critical part of t
Autor:
Jérôme Fayette, A.D. Colevas, Lisa Licitra, Makoto Tahara, Everett E. Vokes, Stefan Kasper, James W. Shaw, Mark Lynch, Francis P. Worden, Joël Guigay, Kevin J. Harrington, Manish Monga, Robert I. Haddad, George R. Blumenschein, Jin Zhu, Robert L. Ferris, Nabil F. Saba, Maura L. Gillison
Publikováno v:
Cancer Research. 77:CT157-CT157
Background: Responses in patients (pts) treated with immune checkpoint inhibitors may occur after initial evidence of radiological disease progression. In CheckMate 141, a randomized phase 3 study of nivolumab (nivo) vs investigator’s choice (IC) o